TY - JOUR
T1 - Characterizing Trends in Synthetic Cannabinoid Receptor Agonist Use from Patient Clinical Evaluations during Medical Toxicology Consultation
AU - On behalf of the IN3 Study Group
AU - Tebo, Collin
AU - Mazer-Amirshahi, Maryann
AU - Wax, Paul
AU - Campleman, Sharan
AU - Boyer, Edward
AU - Brent, Jeffrey
AU - Sheth, Amit
AU - Daniuaityte, Raminta
AU - Carlson, Robert
N1 - Publisher Copyright:
© 2020 Taylor & Francis Group, LLC.
PY - 2021
Y1 - 2021
N2 - Synthetic cannabinoid receptor agonists (SCRAs) are a new class of compounds with profound psychoactive effects and potential toxicity. This study characterizes patterns in SCRA abuse using qualitative interviews with individuals receiving medical toxicology consultation. Patients with suspected exposure to a new psychoactive substance were interviewed by medical toxicologists upon presentation for acute care. Investigators collected clinical and qualitative data including knowledge, attitudes, beliefs, and practices related to psychoactive substance use. Responses were categorized by identifying themes, and statistics were generated to describe patterns of use. Overall, 69% (86) of the 124 cases of novel psychoactive substance use entered into the registry were associated with exposure to SCRAs. Most patients (68.8%) had used SCRAs at least once before the presenting episode. 47.7% considered SCRAs to be very easy to obtain, and 44.2% reported paying for the substances while 32.6% acquired it for free. Nearly half (48.8%) of patients reported their primary reason for use was to get high; a small proportion used SCRAs to avoid testing positive on drug screening (6.9%) or as an alternative to marijuana (4.6%). Findings suggest an independent and stable culture is developing around the use of SCRAs separate from their appeal as an “undetectable” alternative to marijuana.
AB - Synthetic cannabinoid receptor agonists (SCRAs) are a new class of compounds with profound psychoactive effects and potential toxicity. This study characterizes patterns in SCRA abuse using qualitative interviews with individuals receiving medical toxicology consultation. Patients with suspected exposure to a new psychoactive substance were interviewed by medical toxicologists upon presentation for acute care. Investigators collected clinical and qualitative data including knowledge, attitudes, beliefs, and practices related to psychoactive substance use. Responses were categorized by identifying themes, and statistics were generated to describe patterns of use. Overall, 69% (86) of the 124 cases of novel psychoactive substance use entered into the registry were associated with exposure to SCRAs. Most patients (68.8%) had used SCRAs at least once before the presenting episode. 47.7% considered SCRAs to be very easy to obtain, and 44.2% reported paying for the substances while 32.6% acquired it for free. Nearly half (48.8%) of patients reported their primary reason for use was to get high; a small proportion used SCRAs to avoid testing positive on drug screening (6.9%) or as an alternative to marijuana (4.6%). Findings suggest an independent and stable culture is developing around the use of SCRAs separate from their appeal as an “undetectable” alternative to marijuana.
KW - Synthetic cannabinoid receptor agonists
KW - emergency medicine
KW - medical toxicology consultation
KW - novel psychoactive substances
KW - spice
UR - https://www.scopus.com/pages/publications/85096524245
UR - https://www.scopus.com/pages/publications/85096524245#tab=citedBy
UR - https://corescholar.libraries.wright.edu/comhth/604
U2 - 10.1080/02791072.2020.1851826
DO - 10.1080/02791072.2020.1851826
M3 - Article
C2 - 33225872
AN - SCOPUS:85096524245
SN - 0279-1072
VL - 53
SP - 207
EP - 214
JO - Journal of Psychoactive Drugs
JF - Journal of Psychoactive Drugs
IS - 3
ER -